Decreased levels of circulating sRAGE or esRAGE have been reported in patients with hypertension [33], metabolic syndrome (MS) [34], in the early phase of type 2 diabetes [35,36] and obesity suggesting sRAGE as an early predictor of cardiovascular risk. This evidence concerns the gene AGER and type 2 diabetes mellitus.